Diana Chichur, Andrej Sergienko (Kyiv, Ukraine)


The thesis is devoted to improving efficacy of treatment of rhegmatogenous retinal detachment (RRD) patients, aimed to prevent the disease relapse and its development in the fellow eye by using a modified immunosuppressive therapy method, by studying autoimmune process activity in patients with different disease course.


80 patients suffering from bilateral RRD were included in the study.

Effectiveness / Safety:

Two types of bilateral RRD clinical course were distinguished from clinical assessment: type I ˆ favorable, observed in 13.7% of the cases, manifested through its tendency for simultaneous affection of both eyes, absence of vitreoretinal traction, low relapse rate, and high effectiveness of extrascleral sealing reaching 100%; type II ˆ unfavorable, observed in 86.3% of the cases, manifested through successive lesion of eyes, pronounced vitreoretinal traction, frequent use of endovitreal surgery, and decrease of surgical treatment efficacy to 73.7 %. Excessive activation of autoimmune processes and their maintenance has been found to be one of pathogenetic mechanisms of recurrent RRD and bilateral RRD development in 80% of the cases. Efficacy of the suggested treatment scheme was 82.0%: relapse rate in unilateral RRD patients was decreased from 35.7% to 4.2%, and the same parameter in BRRD patients was decreased from 76.9% to 18.8%.

Take home message:

Application of steroids (both systemic and topical) in the treatment of patients with high levels of circulating autoantibodies to ocular tissues (20.0 U and higher) prevents realization of autoimmune cytotoxic reactions, thus decreasing the risk of relapse and RRD development on the fellow eye.